You are here:
telaprevir (Incivo) Naive
Advice
following a full submission:
telaprevir (Incivo®) is accepted for use within NHS Scotland.
Indication under review: in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis) who are treatment-naïve.
In the pivotal phase III randomised study, addition of telaprevir to current standard therapy in treatment-naïve patients with genotype 1 chronic hepatitis C virus, significantly increased the proportion of patients who achieved a sustained virologic response, even in patients treated for a shorter overall duration using response-guided therapy.
Drug Details
| Drug Name: | telaprevir (Incivo) Naive |
|---|---|
| SMC Drug ID: | 743/11 |
| Manufacturer: | Janssen-Cilag Ltd |
| Indication: | In combination with peginterferon alfa and ribavirin (PR), for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis): who are treatment naive |
| BNF Category: | |
| Submission Type: | Full submission |
| Status: | Accepted |
| Date Advice Published: | 12 December 2011 |